🇯🇵

Japan

Asia Pacific

Japan is Asia's most mature biotech market with a strong regulatory framework (PMDA) and deep expertise in regenerative medicine. The country was the first to approve iPSC-derived cell therapies.

Biotech Market Cap

$256.7B

Public Companies

Total Companies

192

30D Performance

-6.21%

BIOTECH MARKET CAP INDEX

$256.7B+1591.6%ALL

BIOTECH HUBS

TokyoOsakaKobeTsukuba

COMPANIES

#	Company	Valuation
1	Chugai Pharmaceutical4519.T	$83.1B
2	Takeda Pharmaceutical	$59.2B
3	Otsuka Holdings4578.T	$37.1B
4	Daiichi Sankyo4568.T	$30.2B
5	Astellas Pharma4503.T	$26.3B
6	Shionogi4507.T	$17.3B
7	Eisai4523.T	$8.4B
8	Kyowa Kirin4151.T	$7.8B
9	Ono Pharmaceutical4528.T	$7.4B
10	Shimadzu Medical Systems7701.T	$7.1B
11	Tosoh Bioscience4042.T	$5.2B
12	Sumitomo Pharma4506.T	$4.1B
13	Rohto Pharmaceutical4527.T	$3.4B
14	Santen Pharmaceutical4536.T	$3.3B
15	KOBAYASHI Pharmaceutical4967.T	$2.8B
16	Nippon Shinyaku4516.T	$1.8B
17	Nipro Corporation8086.T	$1.5B
18	Towa Pharmaceutical4553.T	$1.2B
19	Kissei Pharmaceutical4547.T	$1.2B
20	H.U. Group Holdings4544.T	$1.1B